This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameMolgramostim
Accession NumberDB12525
TypeBiotech
GroupsInvestigational
Description

Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.

Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIB321AL142J
CAS number99283-10-0
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Molgramostim.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Molgramostim.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Molgramostim.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Molgramostim.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Molgramostim.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Molgramostim.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Molgramostim.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Molgramostim.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Molgramostim.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Molgramostim.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Molgramostim.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Molgramostim.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External LinksNot Available
ATC CodesL03AA03 — Molgramostim
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Bronchiectasis / Cystic Fibrosis (CF) / Pulmonary Alveolar Proteinosis (PAP)1
2, 3RecruitingTreatmentAutoimmune Pulmonary Alveolar Proteinosis1
Properties
StateNot Available
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Drug created on October 20, 2016 16:43 / Updated on June 28, 2017 10:03